Otsuka, Lundbeck: Positive Phase 3 Study of REXULTI for Agitation of Dementia Due to Alzheimer’s

 New efficacy data reported for pivotal Study 213 shows significant, clinically meaningful improvements in agitation symptoms.

Agitation symptoms negatively impact functioning, disease progression, quality of life and care for about half of Alzheimer’s dementia patients – and are a consistent predictor of nursing home admission.^5,6

REXULTI^® is the first drug approved by the FDA for agitation associated with dementia due to Alzheimer’s disease.

https://www.biospace.com/article/releases/jama-neurology-publishes-complete-results-of-positive-phase-3-study-of-rexulti-brexpiprazole-for-agitation-associated-with-dementia-due-to-alzheimer-s-disease/